Drug
Disitamab Vedotin
Disitamab Vedotin: highest development phase Phase 2, developed by Pfizer. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Pfizer
Trials
| Drug | Phase | Indication |
|---|---|---|
| disitamab vedotin NCT06003231 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| disitamab vedotin NCT04879329 | Phase 2 | Urothelial Carcinoma |
| Disitamab vedotin NCT06966453 | Phase 1/2 | Breast Cancer |
Latest
No recent events.
Follow Disitamab Vedotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.